XML 23 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total Stockholder's Equity [Member]
Common Stock
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Deferred Compensation [Member]
Noncontrolling Interests [Member]
Series B Preferred Stock
Total
Beginning Balance at Oct. 31, 2019 $ 75,737 $ 19 $ 1,151,454 $ (1,075,089) $ (647) $ (466) $ 466     $ 75,737
Beginning Balance at (in shares) at Oct. 31, 2019   193,608,684                
Sale of common stock, net of fees 171,911 $ 9 171,902             171,911
Sale of common stock, net of fees (in shares)   86,307,932                
Orion warrant exercises and other warrant exercises 37,060 $ 1 37,059             37,060
Orion warrant exercises and other warrant exercises (in shares)   14,696,320                
Common stock issued, non-employee compensation 104   104             $ 104
Common stock issued, non-employee compensation (in shares)   58,303               58,303
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans (3)   (3)             $ (3)
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans (in shares)   49,434                
Share based compensation 1,868   1,868             1,868
Reclassification of value of share based compensation upon approval of authorized shares for grant 401   401             401
Preferred dividends - Series B (3,331)   (3,331)           $ (3,331) (3,331)
Effect of foreign currency translation (92)       (92)         (92)
Adjustment for deferred compensation           34 (34)      
Adjustment for deferred compensation (in shares)   (13,915)                
Net loss (89,107)     (89,107)           (89,107)
Net loss                   (89,107)
Ending Balance at Oct. 31, 2020 194,548 $ 29 1,359,454 (1,164,196) (739) (432) 432     194,548
Ending Balance at (in shares) at Oct. 31, 2020   294,706,758                
Sale of common stock, net of fees 525,895 $ 8 525,887             525,895
Sale of common stock, net of fees (in shares)   69,074,573                
Orion warrant exercises and other warrant exercises 22,093   22,093             22,093
Orion warrant exercises and other warrant exercises (in shares)   2,714,026                
Common stock issued, non-employee compensation 275   275             $ 275
Common stock issued, non-employee compensation (in shares)   31,889               31,889
Share based compensation 4,293   4,293             $ 4,293
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (331)   (331)             (331)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   108,511                
Preferred dividends - Series B (3,200)   (3,200)           (3,200) (3,200)
Effect of foreign currency translation (80)       (80)         (80)
Adjustment for deferred compensation           (154) 154      
Adjustment for deferred compensation (in shares)   (17,019)                
Release of a share reserve   (45)                
Net loss attributable to noncontrolling interest                   (30)
Net loss (101,055)     (101,055)           (101,055)
Net loss                   (101,025)
Ending Balance at Oct. 31, 2021 642,438 $ 37 1,908,471 (1,265,251) (819) (586) 586     $ 642,438
Ending Balance at (in shares) at Oct. 31, 2021   366,618,693               366,618,693
Sale of common stock, net of fees 183,552 $ 4 183,548             $ 183,552
Sale of common stock, net of fees (in shares)   38,396,904                
Common stock issued, non-employee compensation 305   305             $ 305
Common stock issued, non-employee compensation (in shares)   76,848               76,848
Share based compensation 6,792   6,792             $ 6,792
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (1,840)   (1,840)             (1,840)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   539,950                
Preferred dividends - Series B (3,200)   (3,200)           $ (3,200) (3,200)
Effect of foreign currency translation (933)       (933)         (933)
Adjustment for deferred compensation           (269) 269      
Adjustment for deferred compensation (in shares)   (69,407)                
Reclassification of noncontrolling interest               $ 12,419   12,419
Return of capital to noncontrolling interest               (496)   (496)
Distribution to noncontrolling interest               (308)   (308)
Net loss attributable to noncontrolling interest 4,510     4,510       (4,510)   4,510
Net loss                   (142,722)
Net loss (147,232)     (147,232)           (147,232)
Ending Balance at Oct. 31, 2022 $ 684,392 $ 41 $ 2,094,076 $ (1,407,973) $ (1,752) $ (855) $ 855 $ 7,105   $ 691,497
Ending Balance at (in shares) at Oct. 31, 2022   405,562,988               405,562,988